LIB003

BIOLOGICAL3 trials

Sponsors

LIB Therapeutics LLC

Conditions

HypercholesterolemiaLDL Cholesterol

Phase 1

Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003

CompletedNCT03545438

LIB Therapeutics LLCHypercholesterolemia

Start: 2017-10-30End: 2018-06-30Updated: 2018-07-27

Phase 2

Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction

CompletedNCT03549260

LIB Therapeutics LLCLDL Cholesterol

Start: 2018-05-22End: 2018-11-30Updated: 2019-02-18

Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

CompletedNCT03847974

LIB Therapeutics LLCHypercholesterolemia

Start: 2019-02-14End: 2020-08-31Updated: 2022-03-02